Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.86 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.43 |
| ▸ | CTSA | P10619 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389564 | 1.00 | GPBAR1 (0.86) | GPBAR1RXRARXRBRXRGPSEN1 | |
| SCHEMBL1389566 | 1.00 | GPBAR1 (0.86) | GPBAR1RXRARXRBRXRGPSEN1 | |
| SCHEMBL10241009 | 0.94 | GPBAR1 (0.75) | GPBAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL362979 | 0.94 | GPBAR1 (0.75) | GPBAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1390011 | 0.94 | GPBAR1 (0.75) | GPBAR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL364009 | 0.92 | GPBAR1 (1.00) | GPBAR1RXRARXRBPSEN1PSEN2 | |
| SCHEMBL10240955 | 0.92 | GPBAR1 (1.00) | GPBAR1RXRARXRBPSEN1PSEN2 | |
| SCHEMBL1389585 | 0.92 | GPBAR1 (1.00) | GPBAR1RXRARXRBPSEN1PSEN2 | |
| SCHEMBL364261 | 0.92 | GPBAR1 (1.00) | GPBAR1RXRARXRBPSEN1PSEN2 | |
| SCHEMBL362606 | 0.92 | GPBAR1 (1.00) | GPBAR1RXRARXRBPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | claimed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | claimed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885RXRA 1269/4885RXRB 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.